PECAM1 and myotonic dystrophy type 2: Vesicular markers are successfully used as markers of an increased risk of cardiovascular disease complications in obesity, DM2, and metabolic syndrome (perilipin A, cystatin C, CD14, miR21, disulfide isomerase levels on CD31-positive BBs) [3,5,6,7].